A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs XmAb 5871 (Primary)
- Indications Immunological disorders; Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Xencor
- 29 Jun 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 29 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 09 May 2017 According to a Xencor media release, initial data from this trial are expected in late 2018/ early 2019.